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Efficacy of Antiarrhythmic Drugs in
Arrhythmogenic Right Ventricular Cardiomyopathy
A Report From the North American ARVC Registry
Gregory M. Marcus, MD,* David V. Glidden, PHD,† Bronislava Polonsky, MS,‡
Wojciech Zareba, MD, PHD,‡ Lisa M. Smith, MPH,* David S. Cannom, MD,§
N. A. Mark Estes III, MD, Frank Marcus, MD,¶ Melvin M. Scheinman, MD,*
for the Multidisciplinary Study of Right Ventricular Dysplasia Investigators
San Francisco and Los Angeles, California; Rochester, New York; Boston, Massachusetts; and Tucson, Arizona
Objectives This study sought to examine the efficacy of empiric antiarrhythmic drugs in a rigorously characterized cohort of
arrhythmogenic right ventricular cardiomyopathy (ARVC) patients.
Background Antiarrhythmic drugs are important in protecting against ventricular arrhythmias in ARVC, but no studies have
provided data in a group rigorously screened for the disease.
Methods Antiarrhythmic medicines were examined in all subjects with implantable cardioverter-defibrillators (ICDs) en-
rolled in the North American ARVC Registry. A Cox proportional hazards model was used to account for time on
each drug, and a hierarchical analysis was performed for repeated measures within individuals.
Results Ninety-five patients were studied, with a mean follow-up of 480  389 days. Fifty-eight (61%) received beta-
blockers, and these medicines were not associated with an increased or decreased risk of ventricular arrhyth-
mias. Sotalol was associated with a greater risk of any clinically relevant ventricular arrhythmia as defined by
sustained ventricular tachycardia or ICD therapy (hazard ratio [HR]: 2.55, 95% confidence interval [CI]: 1.02 to
6.39, p  0.045), but this was not statistically significant after adjusting for potential confounders. An increased
risk of any ICD shock and first clinically relevant ventricular arrhythmia while on sotalol remained significant af-
ter multivariable adjustment. Those on amiodarone (n  10) had a significantly lower risk of any clinically rele-
vant ventricular arrhythmia (HR: 0.25, 95% CI: 0.07 to 0.95, p  0.041), a finding that remained significant af-
ter multivariable adjustment.
Conclusions In a cohort of well-characterized ARVC subjects, neither beta-blockers nor sotalol seemed to be protective. Evi-
dence from a small number of patients suggests that amiodarone has superior efficacy in preventing ventricular
arrhythmias. (J Am Coll Cardiol 2009;54:609–15) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.052m
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drrhythmogenic right ventricular cardiomyopathy (ARVC)
also known as arrhythmogenic right ventricular dysplasia or
RVD) is a genetically determined cardiomyopathy associated
ith fibrous and fatty replacement of the right ventricular
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009, accepted April 3, 2009.yocardium, ventricular arrhythmias, and sudden cardiac
eath. Although the prevalence of the disease is estimated to be
pproximately 0.02% to 0.1% in the general population (1),
ortality rates range from 4% to 20% in the major studies (2).
n fact, up to 5% of sudden deaths in young adults in the U.S.
nd up to 25% of exercise-related deaths in the Veneto region
n Italy are attributed to ARVC (2).
See page 616
Although an implantable cardioverter-defibrillator (ICD)
s generally recommended as the best therapy to prevent
eath in the setting of ARVC in the U.S. (3), antiarrhyth-
ic drugs also play a major role in the treatment of the
isease. Implantable defibrillators are not as widely available
n many other countries, and first-line therapy even for the
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Antiarrhythmic Drugs in ARVC August 11, 2009:609–15highest-risk patients will often
be antiarrhythmic medicines.
Even in patients with ICDs, an-
tiarrhythmic drugs are often re-
quired to reduce symptoms
caused by premature ventricular
contractions or ventricular tachy-
cardia (VT) and are crucial in
reducing the incidence of ICD
shocks.
Despite the potentially impor-
tant role of antiarrhythmic med-
icine in ARVC, a prospective
study regarding the efficacy of
different agents in a population
igorously determined to have ARVC has not yet been
eported. Current practice is based largely on anecdote,
xtrapolation from other conditions, and studies that did
ot necessarily differentiate among different agents (4). One
f the most cited reports was a European study involving
erial programmed electrical stimulation testing in ARVC
ubjects, suggesting that sotalol therapy associated with
cute prevention of VT/ventricular fibrillation (VF) induc-
ion may be particularly effective (5). To study the effective-
ess of antiarrhythmic drugs in ARVC in a well-
haracterized population, we assessed the efficacy of
ntiarrhythmic drugs prescribed to patients participating in
he North American ARVC study.
ethods
he Multidisciplinary Study of Right Ventricular Dys-
lasia established the North American ARVC Registry,
hich consists of 18 enrolling centers in the U.S. and
anada (Online Appendix), a clinical center at the
niversity of Arizona, a data coordinating center at the
niversity of Rochester, a genetic center at Baylor
ollege of Medicine, 6 core laboratories in the U.S. and
urope, and a National Institutes of Health–appointed
ata and Safety Monitoring Board (Online Appendix).
ndividuals with left bundle branch morphology ventric-
lar arrhythmias or those who showed repetitive prema-
ure ventricular contractions (at least 1,000 during a 24-h
olter study) who also met task force criteria for the
iagnosis of ARVC (6) were included: diagnostic tests,
ncluding copies of 12-lead electrocardiograms, signal-
veraged electrocardiograms, magnetic resonance imag-
ng, right ventricular angiograms, and right ventricular
iopsies were sent to the study’s core laboratories for
linded assessment. The diagnostic test results were sent
o the Data Coordination Center and entered into a
ecure Web-based data management system. The data
ere monitored online, with error notices for items that
id not match field requirements. Based on the interpre-
Abbreviations
and Acronyms
ARVC  arrhythmogenic
right ventricular
cardiomyopathy
CI  confidence interval
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
IQR  interquartile range
VF  ventricular fibrillation
VT  ventricular
tachycardiaation of each test as affected, borderline, or nonaffected, the principal investigator (F.M.) performed final classi-
cation of the phenotype.
For the purposes of this analysis, only individuals who
et the ARVC task force criteria for ARVC and who had
n ICD placed were included. Task force major criteria
nclude severe global or regional dysfunction and/or
tructural abnormality of the right ventricle such as
ilation or aneurysm, fibrofatty replacement of the myo-
ardium on biopsy, an epsilon wave on 12-lead electro-
ardiogram, and autopsy- or biopsy-confirmed family
istory of ARVC; minor criteria include minor regional
r global dysfunction and/or structural abnormality of the
ight ventricle, inverted T waves in the right precordial
eads in the absence of right bundle branch block, late
otentials on signal-averaged electrocardiogram, left
undle branch block VT or more than 1,000 premature
entricular contractions in 24 h, and a family history of
remature sudden death or ARVC; 2 major , 1 major and
minor, or 4 minor criteria are required for diagnosis (6).
ach patient was assigned an ARVC score based on the
iagnostic tests used to make the diagnosis, with 2 points
or fulfilling a major criterion of a category and 1 point
or meeting the minor criteria of a category. Those
ithout an ICD were not included because follow-up
ata regarding medicine changes and arrhythmias were
nsufficiently complete. Also, the ICD subjects provided
uniform group with the ability to detect serial arrhyth-
ias. Initially, patients were excluded if they had an ICD
mplanted before enrollment. Because patients and their
ersonal physicians often became aware of this study after
CD implantation, this severely hampered referral for
nrollment. During the second year of enrollment, the
ata Safety Monitoring Board agreed to allow enroll-
ent of patients whose ICDs were implanted within 6
onths. In the last 2 years of the study, patients were
ermitted to be enrolled if they had an ICD implanted
or fewer than 2 years.
Single- or dual-chamber ICDs were implanted accord-
ng to customary practices at the discretion of the
nrolling center, and referring electrophysiologists made
ll programming decisions regarding rate cutoff criteria
or antitachycardia and shock therapy for ventricular
achyarrhythmias. Ultimately, 45% of the devices were
ual-chamber and the remainder were single-chamber
CDs. All patients received defibrillators capable of
ecording and storing electrogram data for future collec-
ion and interpretation. Patients received routine ICD
ollow-up every 3 to 6 months as well as with any ICD
hocks or symptomatic arrhythmias. Stored electrograms
ere reviewed after any device therapy and with each
cheduled follow-up, and electrograms for all ICD ther-
pies were sent to the ICD core laboratory (Tufts-New
ngland Medical Center, Boston, Massachusetts), where
ll therapies were reviewed by expert electrophysiologists
nd classified as appropriate or inappropriate for sus-
ained ventricular arrhythmias. All ICD therapies were
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August 11, 2009:609–15 Antiarrhythmic Drugs in ARVConsidered, including antitachycardia pacing and shock
herapy.
Each patient was contacted at least once yearly, and
nterim data related to medications, symptoms, documented
rrhythmias, events determined by interrogation of ICDs,
nd medication changes were entered into the database.
edication prescriptions were not standardized and were
etermined by the treating physician.
All subjects signed informed consent approved by the
nstitutional review board of their enrolling center.
tatistical analysis. Normally distributed continuous
ariables are presented as mean  SD and were compared
sing Student t tests. Continuous variables that were not
ormally distributed are expressed as median and inter-
uartile range (IQR) and were compared using the
ilcoxon rank sum test. Categorical variables were
ompared using the chi-square test. Medicines and po-
ential confounders were examined as time-dependent
ovariates in a Cox proportional hazard model (7) to
xamine 1 of 4 different outcomes: any clinically relevant
rrhythmia (defined as sustained VT or VT/VF requiring
CD antitachycardia pacing therapy or ICD shock), any
CD shock (defined as an appropriate ICD discharge for
ventricular arrhythmia), first clinically relevant arrhyth-
ia, or first ICD shock. Using outcomes of any clinically-
elevant arrhythmia or any ICD shock, the same patient
emained in the model and could contribute repeated
ata and potentially multiple outcomes—in these circum-
tances, a Cox model with a robust standard error was
aseline Characteristics of Those With and Without Malignant VenTable 1 Baseline Characteristics of Those With and Without M
Mean age (yrs)
Male
Race
White
Black
Asian/Pacific Islander
Hispanic
Other
NYHA functional class*
I
II
III
IV
Left ventricular ejection fraction (%)†
Right ventricular ejection fraction (%)‡
Maximum 12-lead QRS duration (ms)
Body mass index (kg/m2)
Family history of sudden death§
Previous history of sustained VT or aborted sudden death
Syncope
Previous history of sustained VT, aborted sudden death, or syncope
New York Heart Association (NYHA) functional class was available for 82 participants. †Left v
articipants. ‡Right ventricular ejection fraction by magnetic resonance imaging was available in 41 parti
VT  ventricular tachycardia.sed to account for clustering within individuals (8). The
omparisons were primarily between time on drug versus
ime not on drug; for example, for amiodarone, the
omparison would be between all subjects during the time
hey were receiving amiodarone versus all subjects during
he time they were not receiving amiodarone. Therefore,
he same subject could be in both groups. Potential
onfounders (see the Results section) were added to the
egression model based on previously demonstrated asso-
iations or those typically deemed to be clinically impor-
ant, or having associations with both the predictor and
utcome with values of p  0.1, or changing the
egression coefficient by 10%.
Analyses were performed using Stata version 9.2 (Stata
orp., College Station, Texas). Two-sided p values 0.05
ere considered statistically significant.
esults
inety-five ARVC patients with ICDs were included in the
nalysis and were followed up for a mean 480  389 days.
he median ARVC score (2 points for fulfilling a major
riterion and 1 point for fulfilling a minor criterion) was 4,
ith an IQR of 4 to 5. Over the follow-up period, 235
linically relevant arrhythmias (either sustained VT or ICD
herapy for VT/VF) were observed in 32 patients, with a
ean tachycardia cycle length of 302  45 ms; 49 of these
vents resulted in an appropriate ICD shock. The mean
achycardia cycle length of ventricular arrhythmias resulting
lar Arrhythmiasant Ventricular Arrhythmias
ically-Relevant
cular Arrhythmia
(n  32)
No Clinically-Relevant
Ventricular Arrhythmia
(n  63) p Value
37  15 39  14 0.62
13 (41%) 22 (36%) 0.63
0.58
26 (81%) 56 (90%)
1 (3%) 1 (2%)
2 (6%) 3 (5%)
2 (6%) 2 (3%)
1 (3%) 0
0.38
26 (90%) 50 (94%)
2 (7%) 3 (6%)
1 (4%) 0
0 0
60  8 60  10 0.96
44  9 42  14 0.73
101  18 103  22 0.77
26  5 25  5 0.53
11 (39%) 21 (38%) 0.92
28 (88%) 44 (71%) 0.073
10 (31%) 13 (21%) 0.27
30 (94%) 46 (74%) 0.022
lar ejection fraction by echocardiography or magnetic resonance imaging was available in 76tricualign
Clin
Ventri
entricu
cipants. §Information regarding a family history of sudden death was available in 82 participants.
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Antiarrhythmic Drugs in ARVC August 11, 2009:609–15n an ICD shock was 256  43 ms. There were no deaths.
atient characteristics of those with and without clinically
elevant ventricular arrhythmias are shown in Table 1.
hose with a previous history of sustained VT, aborted
udden death, or syncope (when examined as a group) more
ommonly exhibited a clinically relevant ventricular arrhyth-
ias during the study period (p  0.022).
eta-blockers. Fifty-eight participants took a beta-blocker
t some point during the study for a median duration of 591
ays (IQR 378 to 942 days). The beta-blockers included
tenolol, metoprolol, bisoprolol, and carvedilol. Although
otalol has beta-blocking properties, it was not included in
he beta-blocker group for the purposes of these analyses.
hile taking a beta-blocker, subjects were not significantly
ore or less likely to experience a clinically relevant arrhyth-
ia when compared with those not taking a beta-blocker
hazard ratio [HR]: 1.75, 95% confidence interval [CI]:
.48 to 6.37, p  0.40) or when compared with participants
ot taking any antiarrhythmic medicines or beta-blockers
HR: 0.63, 95% CI: 0.26 to 1.60, p  0.34). Although the
R favored a reduction in any ICD shocks with beta-
locker therapy, this did not reach statistical significance
HR: 0.54, 95% CI: 0.25 to 1.18, p  0.12). Beta-blockers
ere also not associated with risk of first clinically relevant
rrhythmia or first ICD shock. Adjustment for potentially
mportant confounders, including age, sex, New York Heart
ssociation functional class (modeled as an ordinal vari-
ble), left ventricular ejection fraction, a family history of
udden death, a previous history of sustained VT or aborted
udden death, or ARVC score, did not meaningfully change
ny of these results.
In an exploratory analysis, the effects of each individual
eta-blocker were examined. Only atenolol showed a sta-
istically significant association: 20 subjects received atenolol
or a median of 665 days (IQR 188 to 930 days) throughout
he study; while on atenolol, subjects were 75% less likely to
ave a clinically relevant ventricular arrhythmia throughout
he duration of the study (95% CI: 37% to 90% less likely,
ssociations Between Sotalol and Ventricular Arrhythmias in ARVCTable 2 Associations Between Sotalol and Ventricular Arrhythm
Unadj
HR 95%
Any clinically relevant ventricular arrhythmia
On sotalol versus not 2.55 1.02–6
On sotalol versus no antiarrhythmic agents 4.10 1.09–1
Any ICD shock
On sotalol versus not 2.16 1.15–4
On sotalol versus no antiarrhythmic agents 1.97 0.73–5
First clinically-relevant ventricular arrhythmia
On sotalol versus not 2.52 1.24–5
On sotalol versus no antiarrhythmic agents 3.49 1.24–9
First ICD shock
On sotalol versus not 1.59 0.69–3
On sotalol versus no antiarrhythmic agents 1.69 0.60–4Adjusted for age, sex, history of sustained ventricular tachycardia or aborted sudden death, family histo
ARVC  arrhythmogenic right ventricular cardiomyopathy; CI  confidence interval; HR  hazard ratio 0.003), a finding that remained significant after
djusting for the same confounders listed in the above
aragraph (adjusted HR: 0.25, 95% CI: 0.08 to 0.80, p 
.018). This did not seem to be caused by an especially high
ose of atenolol because the median dose was 25 mg daily
IQR 25 to 50 mg). However, none of the individual
eta-blockers (including atenolol) were significantly associ-
ted with any ICD shock (i.e., ICD shock throughout the
tudy duration), first clinically relevant arrhythmia, or first
CD shock.
otalol. Thirty-eight patients were treated with sotalol at
ome point during study follow-up, for a median 644 days
IQR 464 to 1,091 days). Association between sotalol use
nd the outcomes of any clinically relevant arrhythmia, any
CD shock, first clinically relevant arrhythmia, and first
CD shock are shown in Table 2. The median daily dose of
otalol was 240 mg (IQR 160 to 320 mg). The mean
achycardia cycle length of those with ventricular arrhyth-
ias while taking sotalol was significantly slower: 311  41
s versus 292  46 ms in those not taking sotalol (p 
.0009). Although not all associations were statistically
ignificant, the HRs consistently showed no effect or fa-
ored a detrimental effect of sotalol, whether compared with
o sotalol or compared with no other antiarrhythmic agents
nd whether or not potential confounders are taken into
ccount (Table 2). Adjusting for ARVC score did not
eaningfully change any of these results.
To assess whether a dose effect was present, individuals
ho received the upper quartile dose of sotalol (320 mg/day)
ere analyzed alone. Six patients received at least 320 mg of
otalol during the study period, and patients had a worse
utcome on this dose compared with everyone not receiving
20 mg of sotalol (i.e., compared with all participants not
eceiving 320 mg of sotalol): before adjustment for potential
onfounders, HR for any clinically relevant ventricular
rrhythmia was 3.0, 95% CI: 1.1 to 7.9 (p  0.032); after
djustment for potential confounders, the HR was 14.0,
5% CI: 1.6 to 125.1 (p  0.018).
n ARVC
Adjusted*
p Value HR 95% CI p Value
0.045 1.29 0.86–1.92 0.22
0.037 6.50 2.34–18.02 0.001
0.017 2.36 1.09–5.12 0.03
0.18 3.15 0.88–11.3 0.077
0.010 2.46 1.02–5.96 0.046
0.018 7.54 1.54–36.8 0.012
0.28 1.90 0.68–5.36 0.22
0.32 3.83 0.85–17.4 0.81ias i
usted
CI
.39
5.2
.07
.3
.07
.82
.63
.78ry of sudden death, and New York Heart Association functional class.
; ICD  implantable cardioverter-defibrillator.
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August 11, 2009:609–15 Antiarrhythmic Drugs in ARVCmiodarone. Ten participants took amiodarone for a me-
ian of 545 days (IQR 190 to 583 days). The primary
redictor in the amiodarone analyses was time receiving
miodarone, without special consideration (such as blanking
f outcomes) during either amiodarone loading or with-
rawal. While taking amiodarone, participants had a 75%
ower risk of any clinically relevant ventricular arrhythmia
HR: 0.25, 95% CI: 0.07 to 0.95, p  0.041); after
djustment for age, sex, New York Heart Association
unctional class, left ventricular ejection fraction, a family
istory of sudden death, and a previous history of sustained
T or aborted sudden death, participants had a 97%
ecreased risk (HR: 0.03, 95% CI: 0.01 to 0.64, p 0.025).
omparing only with those not taking other antiarrhythmic
rugs, amiodarone was also significantly associated with a
ower risk of any clinically relevant ventricular arrhythmia
HR: 0, p  0.001); after adjustment for potential con-
ounders, this remained significant. Those taking amioda-
one before a first event had an HR of 0 for either any ICD
hock, first clinically relevant arrhythmia, or first ICD shock
of note, an HR of 0 means that all the first events occurred
n those not taking amiodarone before they occurred in
hose taking amiodarone). Figure 1 provides a timeline of
he 10 patients receiving amiodarone, with data on each
ntiarrhythmic medicine used for those patients included.
ther medications. Sixteen participants received angiotensin-
onverting enzyme inhibitors or angiotensin receptor block-
rs during the study, and there was no apparent relationship
 lolatoSrekcolB ateB
D
* **
2
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9
** * * * * *
8
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1
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* ***
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7
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0 200 400 600
10
Figure 1 Timeline of Antiarrhythmic Medicine Use in the 10 AR
Patients Who Received Amiodarone at Any Time During
Each patient is represented by a different number (1 to 10). Vertical gray lines re
tachycardia or implantable cardioverter-defibrillator (ICD) therapy. *ICD shock. ARVetween the use of these medicines and ventricular arrhyth-
ias. Three patients received statins, and there was also no
onsistent association with an increased or decreased risk of
entricular arrhythmias.
iscussion
n this evaluation of antiarrhythmic agents in a cohort of
igorously characterized ARVC patients, we found that
eta-blockers were neither harmful nor protective against
linically relevant ventricular arrhythmias, that sotalol was
ot effective, and that amiodarone, although only received
y a relatively small number of patients, had the greatest
fficacy.
As exemplified by this study and by the fact that no
eaths occurred in these high-risk patients over an average
f more than 1 year of follow-up, ICDs seem to be effective
n preventing death in ARVC patients.
Despite the importance of pharmacologic therapy in
RVC, a study of antiarrhythmic efficacy in a rigorously
haracterized ARVC population has not previously been
eported. The only other study to previously examine
pecific antiarrhythmic agents first determined acute efficacy
f drugs by response to serial testing with programmed
entricular stimulation (5). This European study of origi-
ally 81 patients and more recently updated to 191 patients
9) suggested that sotalol was the most effective agent, and
miodarone did not seem to be particularly useful; however,
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Antiarrhythmic Drugs in ARVC August 11, 2009:609–15critical difference is that this study determined selection of
ntiarrhythmic therapy based on suppression of VT in the
lectrophysiology laboratory. In contrast, ours is the first
tudy to describe the outcome of different antiarrhythmic
rugs chosen empirically by practicing physicians. The acute
ature of assessing drug efficacy in the previous study may
ave been insufficient to allow for full amiodarone loading
nd consequently full antiarrhythmic effect of the drug. One
imitation of this previous study was that subjects were
ncluded if they had either “proven or highly suspected”
RVC. They did prospectively follow up these patients,
gain finding that sotalol was the most effective agent, but
he predictor was the antiarrhythmic agent they were on
hen discharged and did not take into account duration of
herapy or the possibility that medicines may have been
hanged. Finally, ascertainment of the outcome depended
argely on clinical presentation because very few of these
ubjects had ICDs, making the detection of VT incomplete.
espite this limitation and because it was previously the
nly study that evaluated antiarrhythmic drugs in ARVC,
his study is frequently referenced as an indication for sotalol
s a first-line antiarrhythmic agent in ARVC (2,9). In fact,
t may be that electrophysiology-guided antiarrhythmic
herapy is useful in identifying ARVC patients who are
ood candidates for sotalol.
Because the same ARVC patient can have multiple events
i.e., multiple episodes of ventricular arrhythmias and/or
CD therapies) and because medicines can be changed in
he same patient, assessment of individual drug efficacy is
ifficult and complex. By studying prospectively collected
ata in this well-characterized cohort of ARVC patients
ith ICDs using a Cox proportional hazards model in a
ierarchical structure, we were able to report on the efficacy
f a given drug while accounting for the time patients were
aking a particular drug and the fact that there were repeated
easures within individuals.
Beta-blockers are generally recommended for ARVC
atients (3,10). Although these agents are likely safe, we
ound no evidence that they were protective. Because more
han half of all participants were taking a beta-blocker at
ome point during follow-up (61%), it is unlikely that
nsufficient power to detect a meaningful beta-blocker effect
as responsible for this negative finding. However, there
ay be differences among beta-blockers. Notably, atenolol
as significantly associated with a reduced risk of any
linically relevant arrhythmia. Although multiple hypothesis
esting could be responsible for this positive finding, it is
nlikely to fully explain a robust p value of 0.003: even using
he conservative Bonferroni correction for testing 4 beta-
lockers, the threshold p value for statistical significance
ould be 0.05 divided by 4 (or 0.0125). Finally, we cannot
xclude confounding by indication that was not sufficiently
ddressed with our measured potential confounders in our
egression model; in other words, perhaps healthier or
ower-risk individuals (as determined by some unknown/
nmeasured factor) were more likely to receive atenolol. aAlthough previous data have suggested that sotalol might
e especially effective for ARVC patients (5), our data
uggest that it may have no significant protective effect and
ay even be harmful. In general, even after adjusting for
otential confounders, those patients on sotalol were at
igher risk for any clinically relevant ventricular arrhythmia
r ICD shock throughout the study and at higher risk for
he first clinically relevant arrhythmia (whether compared
ith those not on sotalol or those on no antiarrhythmic
rug). Although the point estimate also suggested a higher
isk of first ICD shock, this association was not statistically
ignificant; however, because first ICD shock was the least
ommon outcome, we may have had insufficient power to
etect a statistically significant difference for this particular
utcome. Those taking sotalol had a statistically signifi-
antly slower VT cycle length, suggesting that any proar-
hythmia (if present) was unlikely to be caused by torsades
e pointes, which would be expected to be faster than the
ean 192 beats/min observed. In fact, this slower rate
hows that the sotalol had some effect on the ventricular
yocardium and suggests that it might make arrhythmias
ore tolerable. Although serial QTc measurements may
lso have helped to determine the true potassium-blocking
ffect of sotalol, these measurements were not available for
ach patient every time a medicine or dose was changed.
nce again, there is the possibility that confounding by
ndication played a role: for confounding to explain an
pparent harmful effect of sotalol, one would have to posit
hat those who were more likely to have arrhythmias were
ore likely to receive sotalol. Although this is possible, it
ould seem unlikely to explain the finding that those
eceiving sotalol were at higher risk for their first clinically
elevant ventricular arrhythmia. It is also possible that the
herapies other than sotalol (such as amiodarone) were
imply more efficacious; however, even when compared with
o therapy, sotalol did not seem to be protective. Finally,
lthough we could not detect a protective effect of the
igher doses of sotalol in this study (320 mg or higher,
ased on the highest quartile), the doses of sotalol given
median 240 mg/day, IQR 160 to 320 mg/day) may have
een insufficient, particularly as the successful sotalol expe-
ience described in Europe involved doses of 320 to 480
g/day and up to 640 mg/day in some cases (9).
Although amiodarone was only taken by 10 patients
uring the study, it seemed to have a consistent protective
ffect regardless of the outcome examined or whether or not
otential confounders were taken into account. Because
hose most likely to be at risk for sustained VT or VF would
ore likely be treated with amiodarone, confounding by
ndication would not seem to be responsible for these
ositive findings, particularly because amiodarone reduced
he risk of any clinically relevant arrhythmia (i.e., if any-
hing, confounding by indication would have been expected
o make amiodarone appear less effective than it actually
as). For example, it might generally be thought thatmiodarone would be reserved for those at the highest risk
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August 11, 2009:609–15 Antiarrhythmic Drugs in ARVCf requiring ICD therapy or sustained VT, therefore result-
ng in a false association between amiodarone and higher
isk of arrhythmias. However, even when examining all
ignificant ventricular arrhythmias (including those who had
change in therapy after an arrhythmic event), amiodarone
as still significantly associated with a lower risk. Notably,
e do not have data on medicine-related toxicities other
han proarrhythmia. Given the relatively small number of
atients on amiodarone, the superior efficacy observed
hould be viewed with some caution; in particular, when
onsidering applying these findings to clinical practice, the
ossibility of long-term toxicities, particularly when treating
ounger and otherwise healthy individuals, must still be
uided by clinical judgment.
tudy limitations. As eluded to above, confounding is
ertainly a possibility when dealing with this observational
ata, particularly because the choice of antiarrhythmic
gents was not standardized and was determined by the
iscretion of the treating physician. Confounding by indi-
ation may have played an important role; however, as
entioned previously, it is unlikely that this is sufficient to
xplain all of our findings related to either sotalol or
miodarone. Other unmeasured confounders may be
resent, and only randomization in a prospective experi-
ental study can adequately address this. Although the use
f ICDs to detect arrhythmias increased our sensitivity in
scertainment of the outcome, we cannot exclude the
ossibility that some of the arrhythmias resulting in ICD
herapy may ultimately have spontaneously terminated and
herefore may not have led to lethal or potentially even
ymptomatic tachycardias if the ICD had not been in place.
owever, in individuals with ICDs, the most clinically
elevant outcome is often avoidance of therapies, particularly
voidance of ICD shocks. Because ICD programming was
etermined by the treating providers rather than by a
niformly adopted protocol, it is possible that some ICD
herapies may have differed among participants receiving
ifferent drugs, primarily as a result of differences in ICD
rogramming. Although all rhythms resulting in ICD
herapies were reviewed by the ICD core laboratory, we also
annot exclude the possibility that some arrhythmias may
ave been misclassified, particularly in subjects with single-
hamber devices. Although our exclusion of ARVC subjects
ithout ICDs allowed for study of a uniform group and a
ensitive and specific method of detecting ventricular ar-
hythmia, this may have limited generalizability to lower-
isk ARVC patients without ICDs; importantly, because all
omparisons were performed within this group, this limita-
ion should not have caused any bias (i.e., there is no
imitation to internal validity). Finally, some of the sub-
roup analyses (such as outcomes involving first-occurrence
vents) involved smaller sample sizes that may have been
rone to over-fitting in the multivariate models; however,
he consistent findings for each drug across adjusted and Fnadjusted analyses as well as across different outcomes (any
vent or first event) suggests that the smaller sample sizes
ikely did not cause substantial error. Despite these limita-
ions, the data from this study are uniquely robust in that
hey included only well-characterized ARVC patients and
ensitive and specific outcome data obtained from continu-
us monitoring via implantable devices.
onclusions
n this rigorously characterized North American ARVC
opulation, in which individual empirically prescribed anti-
rrhythmic agents were analyzed as time-dependent covari-
tes, we found that beta-blockers were neither protective
or harmful, that sotalol (at doses generally lower than those
iven in Europe) was not effective, and that amiodarone,
lthough only given to 10 patients, showed superior efficacy
n preventing sustained VT and ICD therapies.
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APPENDIXor participating centers, please see the online version of this article.
